BridgeMD
New treatment option for Plaque Psoriasis
Official title A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
ClinicalTrials.gov ID: NCT06380907
What this study is testing
What is ZL-1102 1% w/w gel BID for 16 weeks?
ZL-1102 1% w/w gel BID for 16 weeks is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for plaque psoriasis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults ≥ 18 years of age.
- Willing and able to provide signed and dated informed consent prior to any study-related procedures, and willing and able to comply with all study...
- Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by Investigator via medical records or in medical history...
- IGA ≥ 2 (5 score system)
- Affected BSA 3%-15% (excluding head)
You likely can't join if
- Other types of psoriasis dominant other than plaque psoriasis (e.g., psoriatic arthritis, pustular, erythrodermic, guttate, palmar, plantar, scalp or...
- Patients with any serious medical/psychiatric condition or clinically significant laboratory abnormality that would prevent study participation or...
- Known or suspected:
- Severe renal insufficiency or hepatic insufficiency.
- History of severe depression or suicidal ideation or behavior within 2 years prior to screening.
- Positive for any of the following tests at screening:
See the full eligibility criteria
- Adults ≥ 18 years of age.
- Willing and able to provide signed and dated informed consent prior to any study-related procedures, and willing and able to comply with all study procedures
- Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by Investigator via medical records or in medical history obtained from the patient, is currently eligible for topical treatment and...
- IGA ≥ 2 (5 score system)
- Affected BSA 3%-15% (excluding head)
- Agree not to have prolonged sun exposure (e.g., recreational) during the study period. Tanning bed use or use of other light-emitting diodes (LEDs) is not allowed.
- Other types of psoriasis dominant other than plaque psoriasis (e.g., psoriatic arthritis, pustular, erythrodermic, guttate, palmar, plantar, scalp or nail disease) or the lesion is not eligible for topical treatment...
- Patients with any serious medical/psychiatric condition or clinically significant laboratory abnormality that would prevent study participation or place the patient at significant risk, as determined by the Investigator.
- Known or suspected:
- Severe renal insufficiency or hepatic insufficiency.
- History of severe depression or suicidal ideation or behavior within 2 years prior to screening.
- Positive for any of the following tests at screening:
- Human immunodeficiency virus (HIV): HIV antibody
- Hepatitis B virus (HBV): hepatitis B surface antigen (HBsAg)/hepatitis B core antibody (HBcAb)/HBV DNA
- Hepatitis C virus (HCV): HCV RNA
- Patients with active tuberculosis (TB) or untreated latent TB per local guidelines.
- History of and/or concurrent condition of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease), or signs/symptoms of IBD at screening that, in the opinion of the Investigator, pose an unacceptable...
- History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to IL-17 antibodies and any human or humanized biological agents.
- Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 3 years before the initiation of study treatment.
- Patients with a history of chronic alcohol or drug abuse within 6 months of the initiation of study treatment, as determined by the Investigator.
- Prior exposure to ZL-1102.
- Patients who have received a live vaccine within 6 weeks prior to dosing on Day 1.
- Females who are pregnant, wishing to become pregnant during the study, or are breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Phillip, Australian Capital Territory, Australia
- Kogarah, New South Wales, Australia
- Kotara, New South Wales, Australia
- Birtinya, Queensland, Australia
- Coorparoo, Queensland, Australia
- Woolloongabba, Queensland, Australia
- Carlton, Victoria, Australia
- Melbourne, Victoria, Australia
- Melbourne E., Victoria, Australia
- Parkville, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phillip, Australian Capital Territory, Australia; Kogarah, New South Wales, Australia; Kotara, New South Wales, Australia; Birtinya, Queensland, Australia; Coorparoo, Queensland, Australia; Woolloongabba, Queensland, Australia and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.